Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials.
Mercado N, Wijns W, Serruys PW, Sigwart U, Flather MD, Stables RH, O'Neill WW, Rodriguez A, Lemos PA, Hueb WA, Gersh BJ, Booth J, Boersma E. Mercado N, et al. J Thorac Cardiovasc Surg. 2005 Aug;130(2):512-9. doi: 10.1016/j.jtcvs.2004.12.049. J Thorac Cardiovasc Surg. 2005. PMID: 16077421 Free article.
Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial).
Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, Teirstein P, Wijns W, Serruys PW, O'Neill WW, Boersma E. Brugts JJ, et al. Among authors: mercado n. Am J Cardiol. 2009 Apr 1;103(7):917-22. doi: 10.1016/j.amjcard.2008.12.017. Epub 2009 Feb 7. Am J Cardiol. 2009. PMID: 19327416 Clinical Trial.
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).
Breeman A, Mercado N, Lenzen M, van den Brand MM, Harrington RA, Califf RM, Topol EJ, Simoons ML, Boersma E; PURSUIT Investigators. Breeman A, et al. Among authors: mercado n. Cardiology. 2002;98(4):195-201. doi: 10.1159/000067321. Cardiology. 2002. PMID: 12566649 Clinical Trial.
Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: The obesity paradox II?
Gruberg L, Mercado N, Milo S, Boersma E, Disco C, van Es GA, Lemos PA, Ben Tzvi M, Wijns W, Unger F, Beyar R, Serruys PW; Arterial Revascularization Therapies Study Investigators. Gruberg L, et al. Among authors: mercado n. Am J Cardiol. 2005 Feb 15;95(4):439-44. doi: 10.1016/j.amjcard.2004.10.007. Am J Cardiol. 2005. PMID: 15695125 Clinical Trial.
Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization.
Hordijk-Trion M, Lenzen M, Wijns W, de Jaegere P, Simoons ML, Scholte op Reimer WJ, Bertrand ME, Mercado N, Boersma E; EHS-CR Investigators. Hordijk-Trion M, et al. Among authors: mercado n. Eur Heart J. 2006 Mar;27(6):671-8. doi: 10.1093/eurheartj/ehi731. Epub 2006 Jan 19. Eur Heart J. 2006. PMID: 16423872
Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial).
Mercado N, Brugts JJ, Ix JH, Shlipak MG, Dixon SR, Gersh BJ, Lemos PA, Guarneri M, Teirstein PS, Wijns W, Serruys PW, Boersma E, O'Neill WW. Mercado N, et al. Am J Cardiol. 2008 Nov 1;102(9):1151-5. doi: 10.1016/j.amjcard.2008.06.035. Epub 2008 Aug 9. Am J Cardiol. 2008. PMID: 18940282 Clinical Trial.
146 results